健心平律丸对高血压病痰湿壅盛型相关危险因素影响的临床研究

发布时间：2018-03-15 22:04

本文选题：健心平律丸　切入点：高血压病　出处：《广州中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的：本研究通过临床设计,观察健心平律丸治疗高血压病痰湿壅盛型患者治疗前后同型半胱氨酸、C-反应蛋白、尿酸水平、血压、临床症状的变化,证明健心平律丸对高血压病痰湿壅盛型患者相关危险因素(HCY、CRP、UA)、血压等的影响,为更好的控制血压、防止高血压的靶器官损害、并发症的出现提供临床新思路。方法：将符合中西医纳入标准的60例患者,按1：1比例随机分为治疗组、对照组,对照组予苯磺酸氨氯地平片5mg qd晨服,治疗组在对照组基础上予加健心平律丸6gtid饭后服,疗程4周。在治疗前后观察患者血压、中医证候积分、同型半胱氨酸、C-反应蛋白、尿酸水平的变化。结果：血压水平：经4周治疗后,两组收缩压、舒张压均下降(P0.01),治疗组收缩压、舒张压较对照组下降明显(P0.05),对照组降压总效率为70%,治疗组总有效率为87%,治疗组降压效果优于对照组(P0.05),有统计学意义。HCY变化：对照组、治疗组治疗后HCY水平均下降(P0.01),治疗组HCY水平明显低于对照组(P0.05),有统计学意义。CRP变化：对照组、治疗组治疗前后CRP水平对比明显下降(P0.01),治疗后组间比较,治疗组CRP水平明显低于对照组(P0.01),有统计学意义。UA变化：两组治疗前后UA水平对比明显下降(P0.01),治疗后组间比较,治疗组UA明显低于对照组(P0.05),有统计学意义。中医证候：对照组与治疗组治疗前后中医证候积分对比明显下降(P0.01),治疗后治疗组中医证候积分明显低于对照组(P0.01),对照组证候疗效总效率为50%,治疗组总有效率为87%,治疗组疗效优于对照组(P0.01),有统计学意义。结论：1、健心平律丸可以辅助降压药物降低高血压病痰湿壅盛型患者的收缩压、舒张压;2、健心平律丸可以改善高血压病痰湿壅盛型患者的临床症状；3、健心平律丸可以降低高血压病痰湿壅盛型患者的HCY、CRP、UA,有效控制高血压病的危险因素；4、健心平律丸无不良反应,可以作为高血压病治疗的安全有效药物。
[Abstract]:Objective: to observe the changes of homocysteine C-reactive protein, uric acid level, blood pressure and clinical symptoms in patients with hypertensives with phlegm-dampness syndrome before and after treatment. It is proved that Jianxin Ping Law pills can affect the risk factors such as HCY and CRP UAU, blood pressure in patients with hypertensives with phlegm and dampness, so as to better control blood pressure and prevent the damage of target organs of hypertension. Methods: 60 patients who met the standard of traditional Chinese and western medicine were randomly divided into treatment group, control group and control group, which were treated with amlodipine benzenesulfonic acid 5mg QD in the morning. On the basis of control group, the treatment group was given 6gtid after meals with Jianxinping Pill for 4 weeks. The blood pressure, TCM syndromes score and homocysteine C-reactive protein were observed before and after treatment. Results: blood pressure: after 4 weeks treatment, systolic blood pressure and diastolic blood pressure were decreased in both groups (P 0.01), while in the treatment group, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were decreased. Compared with the control group, the diastolic blood pressure (DBP) decreased significantly (P 0.05), the total antihypertensive efficiency in the control group was 70 and the total effective rate in the treatment group was 87. The antihypertensive effect in the treatment group was better than that in the control group (P 0.05), and there were significant changes of HCY in the control group. The level of HCY in the treatment group was significantly lower than that in the control group (P 0.01), and the level of HCY in the treatment group was significantly lower than that in the control group (P 0.05). In the control group, the level of CRP in the treatment group was significantly lower than that in the control group before and after treatment (P 0.01), and there was a significant difference between the two groups after treatment. The level of CRP in the treatment group was significantly lower than that in the control group (P 0.01), and there was a significant change in UA: the levels of UA in the two groups decreased significantly before and after treatment, and there was a significant difference between the two groups after treatment. The UA in the treatment group was significantly lower than that in the control group (P 0.05N), which had statistical significance. TCM syndromes in the control group and the treatment group decreased significantly before and after treatment, and after treatment, the score of TCM syndrome in the treatment group was significantly lower than that in the control group (P 0.01), and that in the control group was significantly lower than that in the control group. The total effective rate of syndromes in the treatment group was 50 and the total effective rate in the treatment group was 87. The curative effect of the treatment group was better than that of the control group (P 0.01), which was statistically significant. Conclusion: the Jianxin Pinglu pills can help to reduce the systolic blood pressure of the patients with hypertensives with phlegm dampness and accumulation of phlegm and dampness. The clinical symptoms of the patients with hypertensives with phlegm and dampness obstruction were improved. Jianxin Pinglu pills could reduce the HCYC CRPUAA of patients with hypertensives with phlegm dampness, and effectively control the risk factors of hypertension. There was no adverse reaction in Jianxin Pinglu pills. It can be used as a safe and effective drug for the treatment of hypertension.
【学位授予单位】：广州中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】